Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by GraniteShares Advisors LLC

GraniteShares Advisors LLC trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,137 shares of the biopharmaceutical company’s stock after selling 176 shares during the period. GraniteShares Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $999,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. HealthInvest Partners AB acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $3,495,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Regeneron Pharmaceuticals by 0.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 65,960 shares of the biopharmaceutical company’s stock valued at $57,932,000 after purchasing an additional 552 shares during the last quarter. Everence Capital Management Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 1.9% in the 4th quarter. Everence Capital Management Inc. now owns 3,741 shares of the biopharmaceutical company’s stock valued at $3,286,000 after purchasing an additional 70 shares during the last quarter. Marietta Wealth Management LLC raised its holdings in Regeneron Pharmaceuticals by 0.3% in the 4th quarter. Marietta Wealth Management LLC now owns 7,853 shares of the biopharmaceutical company’s stock worth $6,897,000 after acquiring an additional 20 shares during the period. Finally, SVB Wealth LLC raised its holdings in Regeneron Pharmaceuticals by 40.0% in the 4th quarter. SVB Wealth LLC now owns 1,117 shares of the biopharmaceutical company’s stock worth $981,000 after acquiring an additional 319 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded down $4.42 during trading hours on Tuesday, reaching $894.14. 615,755 shares of the company were exchanged, compared to its average volume of 495,922. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The stock’s fifty day moving average is $956.81 and its two-hundred day moving average is $889.95. The company has a market cap of $98.14 billion, a price-to-earnings ratio of 25.86, a P/E/G ratio of 2.64 and a beta of 0.11. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same period in the prior year, the business earned $10.96 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up .6% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on REGN shares. Bank of America lifted their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday. StockNews.com upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday. Morgan Stanley boosted their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. Barclays boosted their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a report on Tuesday, January 23rd. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $925.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $970.57.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 827 shares of the stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at $1,325,338. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total value of $95,422.00. Following the completion of the sale, the director now owns 18,382 shares in the company, valued at $17,540,472.04. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Bonnie L. Bassler sold 827 shares of the stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,325,338. The disclosure for this sale can be found here. Insiders have sold 13,729 shares of company stock worth $13,124,641 over the last ninety days. Company insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.